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Crystal structure of vancomycin
Martina Schäfer1, Thomas R Schneider2† and George M Sheldrick1*
Background: Vancomycin and other related glycopeptide antibiotics are
clinically very important because they often represent the last line of defence
against bacteria that have developed resistance to antibiotics. Vancomycin is
believed to act by binding nascent cell wall mucopeptides terminating in the
sequence D-Ala–D-Ala, weakening the resulting cell wall. Extensive NMR and
other studies have shown that the formation of asymmetric antibiotic dimers is
important in peptide binding. Despite intensive efforts the crystal structure of
vancomycin has been extremely difficult to obtain, partly because high-resolution
data were unavailable, and partly because the structure was too large to be
solved by conventional ‘direct methods’.
Results: Using low-temperature synchrotron X-ray data combined with new
ab initio techniques for solving the crystallographic phase problem, we have
succeeded in determining the crystal structure of vancomycin at atomic
resolution. The structure provides much detailed information that should prove
invaluable in modelling and mechanistic studies.
Conclusions: Our structure confirms that vancomycin exists as an asymmetric
dimer. The dimer conformation allows the docking of two D-Ala–D-Ala peptides 
in opposite directions; these presumably would be attached to different
glycopeptide strands. In the crystal, one of the binding pockets is occupied by
an acetate ion that mimics the C terminus of the nascent cell wall peptide; the
other is closed by the asparagine sidechain, which occupies the place of a
ligand. The occupied binding pocket exhibits high flexibility but the closed
binding pocket is relatively rigid. We propose that the asparagine sidechain 
may hold the binding pocket in a suitable conformation for peptide docking,
swinging out of the way when the peptide enters the binding pocket.
Introduction
Vancomycin (Fig. 1) and other related glycopeptide antibi-
otics [1,2] are active against Gram-positive bacteria. Clini-
cally, vancomycin is often the last line of defence against
deadly streptococcal and staphylococcal strains such as
Staphylococcus aureus that have developed resistance to
penicillin, methicillin and other b-lactam antibiotics [3,4].
Vancomycin acts by binding the C-terminal D-Ala–D-Ala
peptides of the polymeric lipid-PP-disaccharide-pentapep-
tides, which interferes with the cross-linking of these
chains in the growing peptidoglycan cell wall [1,2]. This
creates a weak point in the resulting cell wall and makes
the bacterial cell susceptible to lysis when the osmotic
pressure varies. The recent emergence of bacteria that are
also resistant to vancomycin is a matter of considerable
concern. This resistance results from the replacement of
many of the D-ala–D-ala terminal peptides by D-Ala–D-
lactate, which binds much less strongly to vancomycin
because an amide NH group (which can make a hydrogen
bond to a carbonyl oxygen in vancomycin) has been
replaced by an oxygen atom. The genetic basis of this resis-
tance has been elucidated in elegant studies by Courvalin,
Walsh and their colleagues [5–7]. Structural information 
is expected to be important in the losing struggle against
antibiotic resistance, but has been difficult to obtain.
Extensive NMR studies [8–14] by Williams and co-workers
have shown that vancomycin and its analogues are predom-
inantly dimeric in solution and that there is a complex cor-
relation between the affinity of these molecules for model
peptides and their degree of dimerization. This group [10]
recently proposed a detailed structure for the dimer of 
the glycopeptide antibiotic eremomycin complexed with
pyrrole-2-carboxylate based upon NMR data, molecular
dynamics and energy minimization. Nevertheless it is clear
that further modelling studies aimed at modifying antibi-
otic structure to circumvent antibiotic resistance would
benefit considerably from detailed crystallographic struc-
tural data of these molecules, in particular vancomycin
itself and its peptide complexes. In many ways the NMR
studies of these dynamic systems and the static but precise
crystallographic structural information are complementary;
it is important to pursue both approaches despite the diffi-
culties involved.
Early attempts to determine the crystal structure of van-
comycin were based on its degradation product, CDP-1, 
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for which crystals could be obtained that diffracted to 0.8Å.
This high resolution X-ray data and the fact that CDP-1
crystallized with one molecule in the asymmetric unit
enabled the structure to be solved by small molecule
‘direct methods’ [15]; it was then one of the largest struc-
tures to have been solved by direct methods. At that time
it was believed that the degradation, which resulted from
the loss of one molecule of ammonia per molecule of van-
comycin, merely involved the conversion of an amide to a
carboxylate. Subsequent NMR investigations [16] revealed
that the degradation also involved a ring enlargement reac-
tion and led to the reorientation of a chlorine atom from
the back face to the front face of the molecule [17]. With
hindsight this explained why CDP-1 has no antibiotic
activity and also why it crystallized as a monomer rather
than as a dimer (as a dimer, it would have been well
outside the range of then available methods for solving the
crystallographic phase problem). Despite intensive efforts
by ourselves and other research groups, it was nearly 20
years before the techniques of X-ray data collection from
weakly diffracting crystals and methods for ab initio struc-
ture solution had progressed sufficiently to address this
task. Ureido-balhimycin was the first true glycopeptide
antibiotic for which crystal structure data were published
[18]; this structure was solved by a new automated Patter-
son interpretation technique [19] that located the four
chlorine atoms in the asymmetric dimer. Two further
structures, solved by improved reciprocal space direct
methods [20], were reported by Eggleston et al. at the
American Crystallographic Association (ACA) meeting in
1994 and an American Chemical Society (ACS) meeting
in 1995, but no structural details are available. Recently,
the combination of the development of techniques for 
collection of low temperature synchrotron data to atomic
resolution from very weakly diffracting crystals and a
breakthrough in ab initio structure solution methods, have
transformed the prospects of solving crystal structures in
the 100 to 1000 atom range, that is, sizes intermediate
between small molecules and macromolecules. Counting
solvent atoms, there are 313 unique non-hydrogen atoms in
the vancomycin structure. We therefore set out to deter-
mine the structure of vancomycin using these new
methods. A preliminary report of this work was presented
at the International Union of Crystallography (IUCr)
meeting in August 1996 (Abstract PS05.04.01).
Results and discussion
Structure solution
Our initial attempts to solve the structure by conven-
tional direct methods, Patterson interpretation or molecu-
lar replacement all proved ineffective. The phase problem
was finally solved by a new real/reciprocal space recycling
technique, programmed by one us, that was inspired by
the ‘Shake & Bake’ approach of Miller et al. [21,22]. The
method starts with multiple sets of random atoms, and
refines the phases by application of the tangent formula in
reciprocal space, with alternate elimination of prospective
atoms in real space [23] to optimize the correlation coeffi-
cient [24] between observed and calculated normalized
structure factors. For vancomycin 2000 random starting
sets were each refined by eight cycles of real/reciprocal
space iteration, leading to one correct solution (recognised
by its correlation coefficient of 57.0% compared with the
next best of 33.5%); the computer time required corre-
sponded to about four VAX-years. Such real/reciprocal
space iteration has now determined a number of previ-
ously unsolved structures with >200 unique atoms, which
represented a point of severely diminishing chances of
success for conventional direct methods [20]. Although the
only limitation on the size of the structure that can be
solved by real/reciprocal space recycling methods appears
to be the speed of the computer, it is still necessary to
measure relatively complete data that extend to atomic
resolution (1.2Å or better).
The uncensored output of the structure solution is shown
in Figure 2; although no chemical information was used 
by the program, the structure is instantly recognizable as
vancomycin. Indeed, only six of the atoms in the antibiotic
dimer are missing, and some of the solvent atoms were also
located. The structure solution also revealed the unex-
pected presence of two chloride ions per antibiotic dimer.
Structure description
The final refined structure consists of an antibiotic dimer,
two chloride ions, one acetate ion and 105 solvent water
molecules. For electrical neutrality one of the carboxyl
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Figure 1
Structural formula of vancomycin.
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groups per dimer must be in the protonated form, but at 
a pH of ~5 it is reasonable to expect this. Figure 3a shows a
stereoview of the dimer in the same orientation as Figure
7a in which the structure of the eremomycin dimer
complex with pyrrole-2-carboxylate is shown in [10]. The
two antibiotic dimers show qualitatively similar conforma-
tions, even for the sugar substituents. Figure 3b,c shows
the two monomers separately. The hydrogen bonding
pattern proposed by Williams and coworkers [10] for dimer
formation is confirmed by the crystal structure, although
different sugar substituents of necessity give rise to differ-
ences in the different glycopeptide antibiotics. Figure 4
shows the electron density at the dimer interface and
binding pockets, which together with the space-filling
model (Fig. 5) illustrates the remarkable complementarity
of the two monomer units at the dimer interface.
One of the binding pockets of the dimer is occupied by an
acetate ion that mimics the binding of the C terminus of
the nascent cell wall peptide, forming hydrogen bonds
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Figure 2
Stereo projection of the unedited structure
obtained by the ab initio solution of the
structure of the vancomycin dimer. The two
vancomycin molecules can be easily
recognized, although no chemical information
was used in the structure solution.
Figure 3
The crystal structure after refinement. 
(a) Stereo projection of the dimer in a similar
orientation to Figure 7a in [10]. The dimer
interface lies approximately in a vertical plane
at right angles to this diagram, and the
pseudo-twofold axis (for all the atoms except
those of the sugars at the top of the diagram)
lies approximately vertical. (b,c) Different
views (not a stereoview) of the two
monomers, in roughly the same orientation as
the structural formula (Fig. 1). The atoms are
conventionally colour coded according to
element type.
with two of the amide NH groups of the vancomycin
peptide backbone and with the -NH2+-CH3 sidechain.
The other binding pocket is not occupied by a ligand,
however, instead the asparagine sidechain has bent around
so that its carbonyl oxygen forms hydrogen bonds (or at
least electrostatic interactions) with the two corresponding
vancomycin NH groups. Although the different occupan-
cies of the binding pockets may be a fortuitous side-effect
of the crystallization conditions used, this result is impor-
tant because it suggests a previously unsuspected mecha-
nistic role for the asparagine sidechain. This sidechain
might hold the binding pocket in a suitable conformation
for peptide docking (Figs 4b and 6); the asparagine would
then swing out of the way when the peptide enters the
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Figure 4
The dimer interface and binding pockets of vancomycin. (a) Electron
density (contoured at 0.8 s); the green lines represent hydrogen
bonds. (b) Hydrogen bonding distances for the same section. In one
monomer the binding pocket is closed by the asparagine sidechain
occupying the place of a ligand, in the other (lower) it is occupied by
an acetate ion which is held in place by three hydrogen bonds. Taking
into account the further hydrogen bonds that a peptide would make
with the two halves of the vancomycin molecule and the twofold
symmetry axis at right angles to this projection, the two bound peptide
chains of the nascent cell wall would be oriented at roughly 180° to
one another. (Figure 4a generated using the program XtalView [30].)
Figure 5
Space filling models of the vancomycin dimer, showing the particularly
close fit of the two monomer units; the dimer interface lies
approximately vertical in this view. (a) Conventional colour coding, but
with the acetate ion in one of the binding pockets shown in yellow
(upper left); the NH2 group of the terminal asparagine amide lies above
the closed binding pocket (lower right). (b) Linear colour ramp for the
thermal displacement amplitudes. The most mobile atoms are orange,
the least mobile blue; pink and purple are intermediate. Although the
binding pocket occupied by an acetate ion is flexible, the binding
pocket closed by the asparagine sidechain is more rigid.
binding pocket from the other side. It should, however, be
noted that some other biologically active glycopeptides
such as ristocetin [1] have a different substituent in place
of the asparagine, but these aromatic substituents are suf-
ficiently rigid to prevent peptide access from one side.
The least-squares fit of the two monomer units (Fig. 7)
shows substantial conformational differences in the binding
pockets and the sugar substituents, but otherwise the fit is
moderately close (root mean square [rms] deviation 1.09Å).
Although the sugars have been suggested to be important
in stabilizing dimer formation [9,25], in vancomycin they
do not appear to take part in any hydrogen bonds with the
opposite monomer unit. Perhaps they serve to orientate the
vancomycin molecule relative to the nascent cell wall, or
they may simply increase the aqueous solubility of the
antibiotic.
Biological implications
Vancomycin and related glycopeptide antibiotics are
effective against Gram-positive bacteria, including many
strains that have evolved to be resistant to b-lactam
antibiotics such as penicillin and methicillin. Van-
comycin is clinically important in the treatment of the
deadly methicillin-resistant Staphylococcus aureus often
responsible for the blood poisoning associated with sur-
gical wounds [3,4]. Unfortunately, vancomycin-resistant
enterococci encountered in hospital intensive care units
have also become significant in the last five years, but
considerable progress has been made in understanding
the genetic basis of this resistance [5–7]. However,
detailed mechanistic and structural information for van-
comycin is essential to devise modified antibiotics, even
if the new drugs only gain a little time.
The crystal structure of vancomycin previously has not
been determined, despite intensive attempts to solve it for
the last 20 years. A combination of improved experimen-
tal techniques and a breakthrough in ab initio phasing
has finally led to the atomic resolution structure reported
here. The structure confirms the dimeric model proposed
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Figure 6
Proposed insertion of the vancomycin dimer
(the two halves of the box represent the two
monomers) between two different polymeric
disaccharide-pentapeptide strands,
preventing linking of the strands. This linking
would require a lysine sidechain to substitute
for the C-terminal D-alanine as shown on the
right of the diagram. For simplicity only the last
three amino acids of the pentapeptide
branches are labelled. This diagram should be
compared with Figure 2 of reference [7].
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Figure 7
Superposition of the two monomers based on a least-squares fit of all
non-sidechain atoms of the two monomers. The major differences are
localized in the regions of the sugars (upper part of figure) and the
binding pockets (lower right). Standard element colours are used for
the atoms.
from NMR studies [8–14]. The two binding pockets
allow the docking of the peptide branches (terminating in
D-Ala–D-Ala) of the immature cell wall glycopeptide
strands to occur from opposite directions. This suggests
that the vancomycin molecule is inserted between differ-
ent glycopeptide strands. Cross-linking of the bound (and
probably neighbouring) peptides is prevented, leading
eventually to weakening and rupture of the cell wall.
There is an unexpected (and possibly fortuitous) differ-
ence between the two binding pockets that could throw
new light on the mechanism of the binding of vancomycin
to the nascent cell wall peptide. Whereas one binding
pocket is occupied by an acetate ion that mimics the
binding to the C terminus of the peptide, in the other the
asparagine sidechain bends to hold the pocket in a closed
and relatively rigid conformation. This mechanism may
serve to hold the binding pocket in a suitable conforma-
tion for complex formation, one that allows free access
for the approach of the peptide from the other side.
Materials and methods
Crystallization, data collection and processing
Vancomycin was purchased from ICN Biomedicals Products Inc. and
used without further purification. Single crystals of vancomycin were
obtained at room temperature (~20ºC) by vapour diffusion in hanging
drops. Vancomycin drops were equilibrated against reservoir solution
containing 10 mM sodium acetate at pH4.6 and 2 M sodium chloride.
The drops consisted of vancomycin at a concentration of 50mg ml–1 in
10 mM HEPES buffer at pH7.0 diluted with an equal volume of reser-
voir solution. Symmetrical octahedral crystals appeared after 1–2 days
and grew to a size of about 0.3 ×0.3 ×0.3 mm3. The crystals are rela-
tively sensitive to X-rays, so to avoid radiation damage data were col-
lected at low temperature. For low temperature data collection, a crystal
was transferred into a solution of 2.2M sodium chloride at pH4.6 con-
taining 30 % (w/w) glycerol as cryoprotectant, and after a few seconds
the crystal was mounted in a loop made from unwound dental floss and
immediately flash cooled.
Initial X-ray investigations using a Siemens Hi-Star multiwire proportional
counter with Cu-Ka radiation from a rotating anode generator gave data
to a resolution limit of 1.7Å. Finally we collected data for vancomycin
using synchrotron radiation (l=0.862Å) at EMBL/DESY, Hamburg 
from 70 to 1.09Å resolution on the BW7B wiggler beamline [26] with
the MAR image-plate scanner, using three passes with different crystal
detector distances and exposure times. All data processing and merging
were performed using the program system HKL [27]. The space group 
is P43212 with cell dimensions a=b=28.48(2) and c=65.82(4)Å (esti-
mated standard deviations [esd] in parentheses). A total of 164960
reflections were measured at –148°C, which were merged to give
11867 unique data. Reflection data statistics are presented in Table 1,
from which it can be seen that the data are essentially complete to
atomic resolution, still a requirement for the successful application of
direct methods.
Structure refinement
The structure was refined against all F2 values using the program
SHELXL-96 [28]. Chemically equivalent 1,2- and 1,3-distances in the
two monomer units were restrained to be equal (with esds of 0.02Å
and 0.04 Å, respectively) but without imposing target values. Distance
restraints [29] were applied to the acetate ion in the binding pocket and
to the disordered group. Planarity restraints were applied to all aromatic
systems and to all sp2-hybridized carbon atoms. In the anisotropic
refinement, rigid-bond restraints were applied to the differences in
mean square displacement amplitudes along 1,2- and 1,3-distances
(esd 0.01 Å2), and weak similarity restraints (esds 0.05Å, or for terminal
atoms, 0.1 Å2) were applied to the corresponding Uij components of
atoms within 1.7Å of each other (including atoms belonging to different
components of disordered groups). The solvent-water atoms, the chlo-
ride and acetate ions were weakly restrained to be approximately
isotropic. A diffuse solvent parameter was refined throughout, and anti-
bumping restraints were automatically generated [28].
Accession numbers
Atomic coordinates, anisotropic displacement parameters and observed
and calculated structure factors have been deposited with the PDB for
immediate release, and atomic coordinates have also been deposited
with the Cambridge Crystallographic Data Centre.
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